Pediatric Hematology and Oncology · 2020 · 21 citations · 15 references
MedicineHematologyOncologyChemotherapyPediatric HematologyStem Cell TransplantationDonor Lymphocyte InfusionHematologic Malignancy TherapyHematopoietic Stem Cell Transplant PharmacotherapyMaintenance ImmunosuppressionMaintenance TherapyAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TransplantationAcute Myeloid Leukemia TreatmentMaintenance Therapy TrialsProphylactic Donor Lymphocyte InfusionTherapeutic Donor Lymphocyte InfusionTransplantation For Hematologic Malignancies
Post-hematopoietic stem cell transplantation (HSCT) maintenance therapy using azacitidine and prophylactic donor lymphocyte infusions (DLI) was implemented for high-risk acute myeloid leukemia. Azacitidine was started on day +60 as a 5 day course every 28 days for 6 cycles. DLI was given every 6 weeks for 3 doses starting after day +120. Ten patients were treated on this protocol. With a 90% one-year disease free survival, we report this post-HSCT maintenance therapy is feasible, safe, and well tolerated.
15
Thomas Schroeder, Elena Rachlis, Gesine Bug et al. · Biology of Blood and Marrow Transplantation · 2014 · 202 citations · Full text
Charles Craddock, Nadira Jilani, Shamyla Siddique et al. · Biology of Blood and Marrow Transplantation · 2015 · 173 citations · Full text
Marcos de Lima, David L. Porter, Minoo Battiwalla et al. · Biology of Blood and Marrow Transplantation · 2013 · 141 citations · Full text
Medicine, Hematology, Immunology +17